Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Inamoto, Yoshihiro  [Clear All Filters]
2020
Inamoto Y, Lee SJ, Onstad LE, Flowers MED, Hamilton BK, Jagasia MH, Martin PJ, Pavletic SZ, Pidala JA, Pusic I, et al. Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. Blood Adv. 2020;4(1):40-46.
Kuno M, Ito A, Maeshima AMiyagi, Taniguchi H, Tanaka T, Inamoto Y, Kurosawa S, Kim S-W, Fukuda T. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Int J Hematol. 2020.
2019
Kawajiri A, Kitano S, Maeshima AMiyagi, Inamoto Y, Tajima K, Takemura T, Tanaka T, Ito A, Okinaka K, Kurosawa S, et al. Association of CD204 macrophages with poor outcomes of malignant lymphomas not in remission treated by allo-HCT. Eur J Haematol. 2019.
Yuda S, Fuji S, Onishi A, Tanaka T, Inamoto Y, Kurosawa S, Kim S-W, Fukuda T. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, DeAngelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, et al. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.
Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringdén O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, et al. Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, et al. Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2019.
Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, et al. Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
2018
Ito R, Inamoto Y, Inoue Y, Ito A, Tanaka T, Fuji S, Okinaka K, Kurosawa S, Kim S-W, Yamashita T, et al. Characterization of late acute and chronic graft-versus-host disease according to the 2014 NIH consensus criteria in Japanese patients. Biol Blood Marrow Transplant. 2018.
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, et al. Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, et al. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2018.
Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, et al. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2018.
Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018.
2016
Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016.
Deol A, Sengsayadeth S, Ahn KWoo, Wang H-L, Aljurf M, Antin JHarry, Battiwalla M, Bornhäuser M, Cahn J-Y, Camitta B, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016.
Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim S-W, Tanosaki R, Fukuda T. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016.
2015
Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, et al. Comparison of Characteristics and Outcomes of Trial Participants and Non-participants: Example of Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Biol Blood Marrow Transplant. 2015.
Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, et al. Failure-free Survival in a Prospective Cohort of Patients with Chronic Graft-Versus-Host Disease. Haematologica. 2015.
2014
Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf D, Pidala J, Flowers MED, Arora M, Jagasia M, Arai S, et al. Association of organ severity with mortality and recurrent malignancy in chronic graft-versus-host disease. Haematologica. 2014.
Arora M, Hemmer MT, Ahn KWoo, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RPeter, Inamoto Y, et al. CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.

Pages